Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes.
about
Adipokines as a novel link between obesity and atherosclerosisThe relationship between gut and adipose hormones, and reproductionInsulin resistance in chronic kidney disease: a systematic review.Obesity, inflammation, and lung injury (OILI): the good.Omentin-1 levels are reduced by pharmacologic doses of leptin, but remain unaffected by energy deprivation and display no day-night variation.Impact of serum omentin-1 levels on cardiac prognosis in patients with heart failure.Serum omentin and vaspin levels in cirrhotic patients with and without portal vein thrombosisStrain-specific copy number variation in the intelectin locus on the 129 mouse chromosome 1.The Effect of 12 Weeks Aerobic, Resistance, and Combined Exercises on Omentin-1 Levels and Insulin Resistance among Type 2 Diabetic Middle-Aged WomenJoint analysis of left ventricular expression and circulating plasma levels of Omentin after myocardial ischemia.Omentin changes following bariatric surgery and predictive links with biomarkers for risk of cardiovascular diseaseInflammation, a link between obesity and cardiovascular diseaseCirculating irisin, omentin-1, and lipoprotein subparticles in adults at higher cardiovascular riskOmentin-1 is decreased in maternal plasma, placenta and adipose tissue of women with pre-existing obesity.Cardioprotective properties of omentin-1 in type 2 diabetes: evidence from clinical and in vitro studies.Effect of biochanin a on serum visfatin level of streptozocin-induced diabetic rats.Decreased levels of serum omentin-1 in patients with inflammatory bowel diseaseAssociation of circulating omentin-1 level with arterial stiffness and carotid plaque in type 2 diabetes.Increased chemerin and decreased omentin-1 levels in morbidly obese patients are correlated with insulin resistance, oxidative stress and chronic inflammation.Reproducibility of Retinol Binding Protein 4 and Omentin-1 Measurements over a Four Months Period: A Reliability Study in a Cohort of 207 Apparently Healthy ParticipantsSerum and Vitreous Concentrations of Omentin-1 in Diabetic RetinopathyOmentin as a novel biomarker of metabolic risk factors.Association of serum omentin levels with cardiac autonomic neuropathy in patients with type 2 diabetes mellitus: a hospital-based study.The effect of enteral nutrition on adipokines in patients with acute pancreatitis.Omentin-1 plasma levels and cholesterol metabolism in obese patients with diabetes mellitus type 1: impact of weight reduction.Correlations Between Abnormal Glucose Metabolism and Bone Mineral Density or Bone MetabolismOmentin-1 Stimulates Human Osteoblast Proliferation through PI3K/Akt Signal Pathway.Changes of serum omentin-1 levels and relationship between omentin-1 and insulin resistance in chronic hepatitis C patients.Cardiac Affection in Type 1 Diabetic Patients in Relation to Omentin.Obesity-Induced Changes in Adipose Tissue Microenvironment and Their Impact on Cardiovascular Disease.Circulating Omentin-1 and Chronic Painful Temporomandibular DisordersEvaluation of the relationship between circulating omentin-1 concentrations and components of the metabolic syndrome in adults without type 2 diabetes or cardiovascular disease.Serum omentin-1 as a disease activity marker for Crohn's disease.Association of serum omentin-1 levels with coronary artery disease.Biomarkers in the field of obesity and its related comorbidities.Adipokines, vascular wall, and cardiovascular disease: a focused overview of the role of adipokines in the pathophysiology of cardiovascular disease.Relationship among plasma adipokines, insulin and androgens level as well as biochemical glycemic and lipidemic markers with incidence of PCOS in women with normal BMI.Adipokines in psoriasis: An important link between skin inflammation and metabolic alterations.Adiponectin and Intelectin-1: Important Adipokine Players in Obesity-Related Colorectal CarcinogenesisAdipose Tissue-Derived Omentin-1 Function and Regulation.
P2860
Q26852200-00D5054D-5EB1-4F39-B041-02A935B07283Q28301116-11559CEF-1310-4468-B9E8-5462E505FCDAQ30244271-9EB43694-405F-4A1D-B3B4-7591082E0B18Q30363313-BB25F976-4916-498B-8C7E-2068FBF26BC2Q30371628-0D61AC82-4E81-47AD-925F-52DBEC232731Q33552771-0E5D518E-7B23-4B6F-A629-3131F6C8768CQ33572695-2B3FC065-222C-445E-9505-6BA5362D0D78Q33821460-688C6A0D-0A86-4A03-946E-BE2D97D05EB4Q33849140-85DE8376-AF8E-4D73-906D-2F7C8102543DQ33883211-A0AC308B-0245-4692-AB80-1B3C9A68E8A7Q34079744-DB687496-FC96-433E-B74A-27D1719EB9F7Q34089724-3D987962-340F-4A7E-8635-5FBE7888A2AFQ34244014-EDBDDD21-F396-4BB1-A7A3-99C8B0D6D071Q34404890-896D7591-22D9-4E0D-8188-6AC6F78FD8A9Q34651892-35380E8C-D558-4C8A-B602-BFBDFB009D39Q34733483-5744D9C9-8620-45A1-9F4B-4F40B9351802Q34982144-61F49983-0F31-4038-BB0B-17BDDF730A96Q35607765-D758CA5B-DE43-435B-9BB6-9F2FB9FFB391Q35713733-FC4C96F1-7A5A-4671-AAB4-A60A2AD1D135Q35786647-E5459BB9-B5CD-4037-94AE-B52267FF55E0Q36069241-7B2A850F-EDA7-474D-AB3B-77A48650CAA4Q36138940-715380D9-FB87-4873-8AB5-83D90CE09F97Q36163654-8C8C9F68-1606-42E1-ABC9-D10CE6AD9DE3Q36177659-83BF41F3-02AA-4E25-8180-A0D46017D2EEQ36245527-714A7964-5D1F-4F38-99B3-7AB454C0478DQ36691678-6B7FE22A-0AC9-4E51-81AF-CF28C6710DA4Q36765609-580A5D2F-22DF-4C8D-B9C5-B92DEB0E517AQ36786928-64B82548-8CDA-4D15-8658-21302AECADE2Q36929499-74480AC7-9ED8-42F9-BE7D-C28EE37F2CE4Q36951691-1AD5AEEE-FF48-46CE-95D1-EDCD0A00B805Q37207319-E96C2224-EA52-41B8-A761-2C27B9406F0CQ37514552-AA99E94D-BCA2-4F08-B373-B18F4DCFC571Q37603086-D1485045-D057-4FEE-8F59-F7CF79D03E89Q37729492-6511CB0E-9942-4802-B0F4-D6DF4A4EBAEAQ38183431-31095B97-CD9B-446C-A3C5-8E5E88BB2F4BQ38188874-5364C91D-5E2B-436D-8CF8-7C638D4B0312Q38864973-9BF0E1ED-A8D2-45F4-8C84-AA9A2151C207Q38935290-54EC463B-0606-45D4-9908-0B7DAD05BF95Q39250237-54AB38C6-496B-4221-B9EE-A1F6C1ED0CDAQ39390964-60631BC0-3B6C-4CBD-B63B-BFAA59311782
P2860
Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Changes of serum omentin-1 lev ...... and untreated type 2 diabetes.
@en
Changes of serum omentin-1 lev ...... and untreated type 2 diabetes.
@nl
type
label
Changes of serum omentin-1 lev ...... and untreated type 2 diabetes.
@en
Changes of serum omentin-1 lev ...... and untreated type 2 diabetes.
@nl
prefLabel
Changes of serum omentin-1 lev ...... and untreated type 2 diabetes.
@en
Changes of serum omentin-1 lev ...... and untreated type 2 diabetes.
@nl
P2093
P1476
Changes of serum omentin-1 lev ...... and untreated type 2 diabetes.
@en
P2093
P356
10.1016/J.DIABRES.2010.01.013
P577
2010-02-02T00:00:00Z